RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
August 4, 2016
Regenerative Medicine Earnings Scorecard - Q2/2016 - to date
August 2, 2016
RegMed Investors’ closing bell analysis, resistance is a culprit in today’s downside
July 28, 2016
RegMed investors’ closing bell analysis: the sector sells-off
July 19, 2016
RegMed investors’ closing bell analysis: Risk aversion pushes the downside even lower
July 15, 2016
RegMed investors’ closing bell analysis: sector’s UP, markets mixed – another inverse relationship
July 5, 2016
RegMed investors’ closing bell analysis: sector loses its footing
June 28, 2016
RegMed investors’ closing bell analysis: a ripple effect
June 28, 2016
Higher open expected; RegMed investors’ pre-open, futures are bouncing up as fear eases
June 27, 2016
RegMed investors’ closing bell analysis: sweating the sell-off damage
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.